[HTML][HTML] Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk
A Mauriello, A Ascrizzi, R Molinari, L Falco, A Caturano… - Genes, 2023 - mdpi.com
Purpose of Review: Advances in pharmacogenomics have paved the way for personalized
medicine. Cardiovascular diseases still represent the leading cause of mortality in the world …
medicine. Cardiovascular diseases still represent the leading cause of mortality in the world …
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk.
A Mauriello, A Ascrizzi, R Molinari, L Falco… - …, 2023 - search.ebscohost.com
Abstract Purpose of Review: Advances in pharmacogenomics have paved the way for
personalized medicine. Cardiovascular diseases still represent the leading cause of …
personalized medicine. Cardiovascular diseases still represent the leading cause of …
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk.
A Mauriello, A Ascrizzi, R Molinari, L Falco, A Caturano… - Genes, 2023 - go.gale.com
Purpose of Review: Advances in pharmacogenomics have paved the way for personalized
medicine. Cardiovascular diseases still represent the leading cause of mortality in the world …
medicine. Cardiovascular diseases still represent the leading cause of mortality in the world …
[PDF][PDF] Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk. Genes 2023, 14, 2057
A Mauriello, A Ascrizzi, R Molinari, L Falco, A Caturano… - 2023 - academia.edu
Purpose of Review: Advances in pharmacogenomics have paved the way for personalized
medicine. Cardiovascular diseases still represent the leading cause of mortality in the world …
medicine. Cardiovascular diseases still represent the leading cause of mortality in the world …
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk
A Mauriello, A Ascrizzi, R Molinari, L Falco… - Genes, 2023 - search.proquest.com
Abstract Purpose of Review: Advances in pharmacogenomics have paved the way for
personalized medicine. Cardiovascular diseases still represent the leading cause of …
personalized medicine. Cardiovascular diseases still represent the leading cause of …
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk
A Mauriello, A Ascrizzi, R Molinari, L Falco, A Caturano… - Genes, 2023 - europepmc.org
Abstract Purpose of Review: Advances in pharmacogenomics have paved the way for
personalized medicine. Cardiovascular diseases still represent the leading cause of …
personalized medicine. Cardiovascular diseases still represent the leading cause of …
[HTML][HTML] Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk
A Mauriello, A Ascrizzi, R Molinari, L Falco, A Caturano… - Genes, 2023 - ncbi.nlm.nih.gov
Abstract Purpose of Review: Advances in pharmacogenomics have paved the way for
personalized medicine. Cardiovascular diseases still represent the leading cause of …
personalized medicine. Cardiovascular diseases still represent the leading cause of …
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk
A Mauriello, A Ascrizzi, R Molinari, L Falco… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose of review Advances in pharmacogenomics have paved the way for personalized
medicine. Cardiovascular diseases still represent the leading cause of mortality in the world …
medicine. Cardiovascular diseases still represent the leading cause of mortality in the world …
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk.
A Mauriello, A Ascrizzi, R Molinari, L Falco, A Caturano… - Genes, 2023 - europepmc.org
Pharmacogenomics has the potential to improve patient care by providing the right drug to
the right patient and could guide the identification of new drug therapies for cardiovascular …
the right patient and could guide the identification of new drug therapies for cardiovascular …